Greenwich LifeSciences, Inc. (GLSI)
Stock Price:
$4.31 USD
-0.44 (-9.26%)
Updated Oct 21, 2020 9:54 AM EDT - Market open
Key Info
| Market Cap |
42.87M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-3.52M |
| Shares Out |
11.95M |
| EPS (ttm) |
-0.29 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 21, 2020 |
| Last Price |
$4.31 |
| Previous Close |
$4.75 |
| Change ($) |
-0.44 |
| Change (%) |
-9.26% |
| Day's Open |
4.70 |
| Day's Range |
4.31 - 4.70 |
| Day's Volume |
137 |
| 52-Week Range |
4.07 - 5.75 |
More Stats
| Market Cap |
42.87M |
| Enterprise Value |
43.50M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
11.95M |
| Float |
n/a |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.29 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3,201 |
| Short Ratio |
0.02 |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
n/a |
| Revenue |
n/a |
| Operating Income |
n/a |
| Net Income |
-3.52M |
| Free Cash Flow |
n/a |
| Net Cash |
-628,319 |
| Net Cash / Share |
-0.06 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | - | - |
| Operating Income | -3.43 | -1.69 |
| Net Income | -3.43 | -1.69 |
| Shares Outstanding | 2.26 | 0.20 |
| Earnings Per Share | -1.52 | -8.32 |
| Operating Cash Flow | -0.29 | -0.11 |
| Free Cash Flow | -0.29 | -0.11 |
| Cash & Equivalents | 0.01 | 0.09 |
| Total Debt | 0.64 | 0.42 |
| Net Cash / Debt | -0.63 | -0.34 |
| Assets | 0.03 | 0.11 |
| Liabilities | 1.38 | 10.23 |
| Book Value | -1.35 | -10.12 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Greenwich LifeSciences, Inc. |
| Country |
United States |
| Employees |
3 |
| CEO |
Snehal Patel |
Stock Information
| Ticker Symbol |
GLSI |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: GLSI |
| IPO Date |
September 25, 2020 |
Description
Greenwich LifeSciences, a clinical stage biopharmaceutical company, focuses on the development of cancer immunotherapies for breast cancer and other human epidermal growth factor receptor 2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was founded in 2006 and is based in Stafford, Texas.